Haitham Mirghani1, Carine Bellera2, Jessy Delaye3, Gilles Dolivet4, Nicolas Fakhry5, Alexandre Bozec6, Renaud Garrel7, Olivier Malard8, Franck Jegoux9, Philippe Maingon10, Jérome Sarini11, Georges Noel12, Suzy Duflo13, Stéphane Temam14, Jean-Louis Lefebvre15, Valérie Costes-Martineau16. 1. Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: haitham.mirghani@aphp.frr. 2. Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux, France. 3. UNICANCER, Paris, France. 4. Department of Head and Neck Surgery, Centre Alexis Vautrin, Nancy, France. 5. Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Marseille, France. 6. Institut Universitaire de la Face et du Cou, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France. 7. Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Montpellier, France. 8. Department of Otorhinolaryngology and Head and Neck Surgery, Nantes University Hospital, 1 Place Alexis-Ricordeau, Nantes, France. 9. Department of Otorhinolaryngology and Head and Neck Surgery, Rennes University Hospital, 2 Rue Henri Le Guilloux, Rennes, France. 10. Radiation Oncology Department, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Sorbonne University, Paris, France. 11. Department of Head and neck Surgery, Institut Claudius Regaud, Toulouse, France. 12. Radiation Oncology Department, Paul Strauss Cancer Centre, Strasbourg, France. 13. Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Guadeloupe, Pointe-à-Pitre, Guadeloupe, France. 14. Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France. 15. Department of Head and Neck Oncology, Oscar Lambret, Lille, France. 16. Department of Biopathology, University Hospital of Montpellier, France.
Abstract
BACKGROUND: France has one of the highest incidence of head and neck cancers in Europe. Despite this, the epidemiological impact of high-risk human papilloma virus (HR-HPV) remains poorly investigated. METHODS: We prospective assessed the proportion of oropharyngeal cancers due to HR-HPV in 15 hospitals throughout France. HPV-status was determined by p16-immunohistochemistry, and by detection of HPV-DNA using in situ hybridization. Cancers were classified as HPV-driven if both p16-immunohistochemistry and HPV-DNA assays were positive. Demographical and clinical features were recorded. RESULTS: 291 patients with palatine-tonsil or tongue-base cancers were recruited from March-2011 to July-2012. Of these, 43.1% of samples were p16-positive and 37.7% were positive for both p16 and HPV-DNA. Prognosis was significantly better in patients with HPV-driven cancers, with smoking negatively impacting patients' oncological outcomes. CONCLUSION: In France, more than a third of tonsillar and tongue base cancers are HPV-driven. More research concerning the evolution of HPV-driven cancers over time is needed.
BACKGROUND: France has one of the highest incidence of head and neck cancers in Europe. Despite this, the epidemiological impact of high-risk human papilloma virus (HR-HPV) remains poorly investigated. METHODS: We prospective assessed the proportion of oropharyngeal cancers due to HR-HPV in 15 hospitals throughout France. HPV-status was determined by p16-immunohistochemistry, and by detection of HPV-DNA using in situ hybridization. Cancers were classified as HPV-driven if both p16-immunohistochemistry and HPV-DNA assays were positive. Demographical and clinical features were recorded. RESULTS: 291 patients with palatine-tonsil or tongue-base cancers were recruited from March-2011 to July-2012. Of these, 43.1% of samples were p16-positive and 37.7% were positive for both p16 and HPV-DNA. Prognosis was significantly better in patients with HPV-driven cancers, with smoking negatively impacting patients' oncological outcomes. CONCLUSION: In France, more than a third of tonsillar and tongue base cancers are HPV-driven. More research concerning the evolution of HPV-driven cancers over time is needed.
Authors: Jean-Luc Prétet; Véronique Dalstein; Antoine Touzé; Agnès Beby-Defaux; Patrick Soussan; Élise Jacquin; Philippe Birembaut; Christine Clavel; Christiane Mougin; Alexandra Rousseau; Jean Lacau Saint Guily Journal: Clin Exp Med Date: 2022-02-23 Impact factor: 3.984
Authors: Steve Durante; Vincent Dunet; François Gorostidi; Periklis Mitsakis; Niklaus Schaefer; Judith Delage; John O Prior Journal: EJNMMI Res Date: 2020-05-07 Impact factor: 3.138
Authors: Philippe Gorphe; Pierre Blanchard; Gabriel C T E Garcia; Marion Classe; Caroline Even; Stéphane Temam; Ingrid Breuskin Journal: BMC Cancer Date: 2022-09-20 Impact factor: 4.638